Beximco faced another quarter of declining profits despite growing revenue, as external headwinds including increased production costs took their toll on the firm.
Bangladeshi generics giant Beximco Pharmaceuticals Ltd. continued its quarterly trend of declining profits, despite net revenue growth, as macroeconomic factors dragged down its bottom line.
The firm has been warning shareholders of this anticipated decline for some time now, cautioning in November that headwinds such as the war in Ukraine, supply chain disruptions and record depreciation of local currency were likely to have an impact from Q1 2023 onward
Viatris continues to make progress on remediation at the firm’s stricken manufacturing facility in Indore, India, following a warning letter and import alert delivered at the tail end of 2024.
Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.
Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.
Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.
Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.
Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.
Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.
